Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256108 · ClinicalTrials.gov registry record · Phase 1
Assessment of Abuse Potential of Cebranopadol in Humans
A Phase 1 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05256108: Completed Phase 1 study, sponsored by Tris Pharma.
NCT05256108 is a Phase 1 study that has completed, run by Tris Pharma. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05256108, a Phase 1 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
Primary Outcome
The scale is a 0-100-point scale: 0 = "Strong disliking"; 50 = "Neither like nor dislike"; 100 = "Strong liking"
Interventions
- DRUG Placebo
- DRUG Cebranopadol 600 µg
- DRUG Oxycodone 40 mg
- DRUG Tramadol 600 mg
- DRUG Cebranopadol 1000 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 1 |
What the finished NCT05256108 record still lists
NCT05256108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05256108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05256108 about?
NCT05256108 is a clinical study titled "Assessment of Abuse Potential of Cebranopadol in Humans". This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
What is the current status of trial NCT05256108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-03-28. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT05256108?
The interventions under investigation include: Placebo (DRUG), Cebranopadol 600 µg (DRUG), Oxycodone 40 mg (DRUG), Tramadol 600 mg (DRUG), Cebranopadol 1000 µg (DRUG).
Who is sponsoring clinical trial NCT05256108?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05256108's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI